Noting this association, it has been hypothesized that ibrutinib may have further therapeutic utility in HER2-positive breast cancer by providing the opportunity to target both kinases simultaneously as this combination should occur in a significant percentage of HER2-positive breast cancers [31]. Here, ERBB2 is linked to breast carcinoma.